Harnessing artificial intelligence and digital technologies across the biopharma value chain
Introduction Artificial intelligence (AI) has the potential to revolutionize drug development through improved efficiency, accuracy, and speed. However, research indicates that biopharma companies have been slow in using AI and digital technologies compared to other industries. This article explores the key considerations in using AI, application areas in biopharma, and how leading CRO/CDMO Syngene uses […]
Antibody Drug Conjugates Re-emergence of an old modality for targeted therapies
Introduction Antibody drug conjugates (ADCs) are a class of targeted drugs composed of a cytotoxic payload linked to an antibody that targets a cancer cell, designed to release the payload specifically at a tumor site to kill the tumor. ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted […]
Quality management paradigm shift: Risk-centric practices take center stage
Introduction The pharmaceutical industry is witnessing a paradigm shift in quality management (QM) as risk-based approaches become integral to ensuring compliance and efficiency. With the rise of advanced therapy medicinal products (ATMPs) and cell and gene therapies (CGTs), contract development and manufacturing organizations (CDMOs) are adopting data-driven and digitalized processes to manage quality risks effectively. […]
Protein therapeutics to amp-up outsourcing in animal health
Introduction The animal health industry is experiencing rapid growth, driven by increasing pet ownership and rising demand for advanced veterinary treatments. Protein therapeutics, particularly monoclonal antibodies (mAbs), and long-acting biologics (LAIs), are transforming the sector, with blockbuster drugs like lokivetmab (Cytopoint) and frunevetmab (Solensia) paving the way for future innovations. Chronic conditions such as diabetes, […]
CROs at the High Table of Drug Discovery
Introduction Contract Research Organizations (CROs) have evolved from simple service providers to key strategic partners in drug discovery. Initially, pharmaceutical companies outsourced limited tasks to reduce costs, but today, they collaborate with CROs throughout the entire drug discovery process, from ideation to early clinical trials. This shift reflects Big Pharma’s growing confidence in CROs’ expertise […]
Inside the growing precision therapy market and the crucial role of pDNA manufacturing
Introduction The precision therapy market is rapidly expanding, driven by breakthroughs in mRNA-based treatments, viral vector-based gene therapies, and gene-modified cell therapies. A crucial component enabling these advancements is plasmid DNA (pDNA). However, pDNA manufacturing presents several challenges, such as manufacturing for small patient populations, meeting sustainability requirements, conforming to the exacting quality standards of […]
Antibody Drug Conjugates: Re-emergence of an old modality for targeted therapies
Introduction Antibody drug conjugates (ADCs) are a class of targeted drugs composed of a cytotoxic payload linked to an antibody that targets a cancer cell, designed to release the payload specifically at a tumor site to kill the tumor. ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted […]